Univariate analysis
| Variable (n) | Hazard ratio (95% CI) | p Value |
|---|---|---|
| *Diuretic controllable ascites were included. | ||
| AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, α fetoprotein; HBsAg, hepatitis B surface antigen; HCVAb, anti-hepatitis C virus antibody. | ||
| Age (y) ⩾65 | 1.34 (1.04–1.73) | 0.026 |
| Male sex (293) | 1.02 (0.769–1.36) | 0.87 |
| HBsAg positive (39) | 1.04 (0.685–1.57) | 0.87 |
| Anti-HCVAb positive (336) | 0.682 (0.494–0.943) | 0.02 |
| Drinking >80 g/day (90) | 1.09 (0.807–1.47) | 0.58 |
| Ascites present (86)* | 2.39 (1.82–3.15) | <0.0001 |
| Encephalopathy present (27) | 1.42 (1.14–1.76) | 0.0015 |
| Albumin g(/dl) | ||
| >3.5 (192) | 1 | |
| 2.8–3.5 (183) | 1.99 (1.52–2.59) | <0.0001 |
| <2.8 (28) | 3.13 (2.01–4.88) | <0.0001 |
| Bilirubin (mg/dl) | ||
| <1 (271) | 1 | |
| 1–2 (110) | 1.19 (1.03–1.36) | 0.016 |
| >2 (22) | 1.48 (1.26–1.72) | <0.0001 |
| Prothrombin time | ||
| >70% (225) | 1 | |
| 40–70% (172) | 1.36 (0.1.05–1.77) | 0.021 |
| <40% (6) | 4.43 (1.79–10.99) | 0.0013 |
| Platelet count ⩾10×103/mm3 (173) | 0.640 (0.494–0.829) | 0.00063 |
| AST >80 IU/l (178) | 0.798 (0.620–1.03) | 0.079 |
| ALT >80 IU/l (166) | 0.771 (0.598–0.994) | 0.045 |
| Size of tumour (cm) | ||
| <2.0 (134) | 1 | |
| 2.0–5.0 (234) | 2.31 (1.70–3.13) | <0.0001 |
| >5.0 (35) | 3.73 (2.37–5.86) | <0.0001 |
| No of nodules | ||
| Single (215) | 1 | |
| 2–3 (135) | 1.18 (0.896–1.57) | 0.24 |
| >3 (53) | 2.13 (1.499–3.03) | <0.0001 |
| Lobar distribution | ||
| Unilobar (292) | 1 | |
| Bilobar (111) | 1.27 (1.11–1.45) | <0.0001 |
| Extrahepatic metastasis present (3) | 20.1 (6.12–66.3) | <0.0001 |
| Portal vein invasion present (4) | 14.6 (4.5–47.6) | <0.0001 |
| AFP (ng/ml) | ||
| <100 (308) | 1 | |
| 100–400 (58) | 1.99 (1.43–2.76) | <0.0001 |
| >400 (37) | 3.57 (2.46–5.18) | <0.0001 |